A Polish medical university is offering innovative pharmaceutical composition for the treatment of androgenetic alopecia and/or acne vulgaris under license agreement
A leading Polish medical university has developed an innovative medicinal product, based on roxithromycinfor, that can be used for treatment of acne vulgaris and androgenetic alopecia. It is now looking for foreign licensees that are willing to obtain IP rights to this formula and introduce it to the market.